RESUMEN
INTRODUCTION: Despite advancements in implantable cardioverter-defibrillator (ICD) technology, sudden cardiac death (SCD) remains a persistent public health concern. Chagas disease (ChD), prevalent in Brazil, is associated with increased ventricular tachycardia (VT) and ventricular fibrillation (VF) events and SCD compared to other cardiomyopathies. METHODS: This retrospective observational study included patients who received ICDs between October 2007 and December 2018. The study aims to assess whether mortality and VT/VF events decreased in patients who received ICDs during different time periods (2007-2010, 2011-2014, and 2015-2018). Additionally, it seeks to compare the prognosis of ChD patients with non-ChD patients. Time periods were chosen based on the establishment of the Arrhythmia Service in 2011. The primary outcome was overall mortality, assessed across the entire sample and the three periods. Secondary outcomes included VT/VF events and the combined outcome of death or VT/VF. RESULTS: Of the 885 patients included, 31% had ChD. Among them, 28% died, 14% had VT/VF events, and 37% experienced death and/or VT/VF. Analysis revealed that period 3 (2015-2018) was associated with better death-free survival (p = .007). ChD was the only variable associated with a higher rate of VT/VF events (p < .001) and the combined outcome (p = .009). CONCLUSION: Mortality and combined outcome rates decreased gradually for ICD patients during the periods 2011-2014 and 2015-2018 compared to the initial period (2007-2010). ChD was associated with higher VT/VF events in ICD patients, only in the first two periods.
Asunto(s)
Cardiomiopatías , Desfibriladores Implantables , Taquicardia Ventricular , Humanos , Cardiomiopatías/etiología , Muerte Súbita Cardíaca/epidemiología , Muerte Súbita Cardíaca/prevención & control , Muerte Súbita Cardíaca/etiología , Desfibriladores Implantables/efectos adversos , América Latina , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/terapia , Taquicardia Ventricular/etiología , Fibrilación Ventricular/diagnóstico , Fibrilación Ventricular/terapia , Fibrilación Ventricular/etiología , Estudios RetrospectivosRESUMEN
BACKGROUND Electrical storm is a rare but potentially life-threatening syndrome characterized by recurrent ventricular arrhythmias. Liver transplant recipients are at increased risk of developing electrical storms due to conditions that prolong QT intervals, such as cirrhotic cardiomyopathy. However, limited information exists on electrical storms in this specific population. This case report presents a patient who experienced 13 cardiac arrests during ventricular fibrillation following liver transplantation. CASE REPORT A 61-year-old woman with a medical history of diabetes, obesity, and cirrhosis due to non-alcoholic fatty liver disease underwent liver transplantation using a deceased donor's liver. Following the procedure, she developed a deterioration in her respiratory function, necessitating orotracheal intubation. Approximately 21 hours post-surgery, she experienced cardiac arrest during ventricular fibrillation, which was rapidly reversed with electrical defibrillation. However, the patient entered a state of electrical storm. Management involved antiarrhythmic medications and temporary transvenous cardiac pacing. She remained stable for 40 hours, but a dislodgment of the device triggered another episode of ventricular fibrillation, leading to her death. CONCLUSIONS This case report highlights the clinical presentation and challenges in managing electrical storms in liver transplant recipients. We hypothesize that cirrhotic cardiomyopathy could be the cause of her recurrent ventricular arrhythmias. Further studies are needed to better understand the underlying mechanisms and risk factors of this life-threatening syndrome in this population, which may enhance risk stratification and enable earlier intervention.
Asunto(s)
Cardiomiopatías , Paro Cardíaco , Trasplante de Hígado , Femenino , Humanos , Persona de Mediana Edad , Fibrilación Ventricular/terapia , Fibrilación Ventricular/complicaciones , Trasplante de Hígado/efectos adversos , Arritmias Cardíacas/etiología , Paro Cardíaco/terapia , Paro Cardíaco/complicaciones , Cirrosis Hepática/complicaciones , Cardiomiopatías/complicacionesRESUMEN
Ventricular fibrillation (VF) is a deadly rhythm problem. With asystole, it represents one of the most extreme emergencies that may engage vital prognosis within only few minutes if appropriated treatment is not instituted. It is learned in all medical schools worldwide that VF is not compatible with consciousness and sustained life. Moreover, at 37°C, and without restauration of cardiac flow, VF may be responsible for severe and most often irreversible brain damage after 3 minutes.
Asunto(s)
Paro Cardíaco , Fibrilación Ventricular , Humanos , Fibrilación Ventricular/terapia , Arritmias Cardíacas , Paro Cardíaco/diagnóstico , Paro Cardíaco/terapia , PronósticoRESUMEN
The goal of this study was to identify how often 2 independent centers defibrillated patients within the American Heart Association recommended 2-minute time interval following ventricular fibrillation/ventricular tachycardia arrest. A retrospective chart review revealed significant delays in defibrillation. Simulation sessions and modules were implemented to train nursing staff in a single nursing unit at a Philadelphia teaching hospital. Recruited nurses completed a code blue simulation session to establish a baseline time to defibrillation. They were then given 2 weeks to complete an online educational module. Upon completion, they participated in a second set of simulation sessions to assess improvement. First round simulations resulted in 33% with delayed defibrillation and 27% no defibrillation. Following the module, 77% of the second round of simulations ended in timely defibrillation, a statistically significant improvement ( P < 0.00001). Next steps involve prospective collection of the code blue data to analyze improvement in real code blue events.
Asunto(s)
Reanimación Cardiopulmonar , Paro Cardíaco , Taquicardia Ventricular , Humanos , Fibrilación Ventricular/terapia , Cardioversión Eléctrica/métodos , Estudios Prospectivos , Estudios Retrospectivos , Mejoramiento de la Calidad , Taquicardia Ventricular/terapia , Paro Cardíaco/terapiaRESUMEN
Electrical storm (ES) is a life-threatening condition that may lead to recurrent arrhythmias, need for ventricular mechanical support, and death. The study aimed to assess the burden of arrhythmia recurrence and in-hospital outcomes of patients admitted for ES in a large urban hospital. We performed a retrospective analysis of patients admitted with ventricular arrhythmias from January 2018 to June 2021 and identified 61 patients with ES, defined as 3 or more episodes of ventricular tachycardia (VT) or ventricular fibrillation (VF) within 24 hours. We reviewed the in-hospital outcomes and compared outcomes between patients who had no recurrence of VT/VF after the first 24 hours (34 [56%]), those with recurrence of 1 or 2 episodes of VT/VF within a 24-hour period (15 [24%]), and patients with 3 or more recurrent VT/VF events consistent with recurrent ES after the first 24 hours (12 [20%]). Patients with recurrent ES had significantly higher in-hospital mortality as compared with those with recurrent VT/VF not meeting criteria for ES or no recurrences of VT/VF (3 [25%] vs 0 [0%] vs 0 [0%]; p = 0.002). Moreover, patients with recurrent ES also had higher rates of the combined end points of ventricular mechanical support and death (7 [58%] vs 1 [6%] vs 1 [3%], p <0.001), invasive mechanical ventilation and death (10 [83%] vs 2 [13%] vs 2 [6%], p <0.001), catheter ablation or death (12 [100%] vs 7 [47%] vs 12 [35%], p <0.001) and heart transplantation and death (3 [25%] vs 2 [13%] vs 0 [0%], p = 0.018). In conclusion, patients admitted with ES have a high risk of in-hospital recurrence, associated with extremely poor outcomes.
Asunto(s)
Ablación por Catéter , Desfibriladores Implantables , Taquicardia Ventricular , Arritmias Cardíacas/etiología , Desfibriladores Implantables/efectos adversos , Humanos , Recurrencia , Estudios Retrospectivos , Taquicardia Ventricular/epidemiología , Taquicardia Ventricular/etiología , Taquicardia Ventricular/terapia , Resultado del Tratamiento , Fibrilación Ventricular/epidemiología , Fibrilación Ventricular/etiología , Fibrilación Ventricular/terapiaRESUMEN
Resumen: Se presenta una serie de 4 casos clínicos de pacientes con y sin cardiopatía estructural, que tuvieron uno o más episodios de tormenta arrítmica. Se describen los tratamientos con sus resultados y una revisión bibliográfica con los avances en el tema más allá de la ablación con catéter.
Abstract: We present 4 clinical cases of patients with and without structural heart disease, who had one or more episodes of arrhythmic storm. Treatments, results and a bibliographic review with advances beyond catheter ablation are described.
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Anciano , Fibrilación Ventricular/terapia , Arritmias Cardíacas/terapia , Ganglio Estrellado , Simpatectomía , Resultado del Tratamiento , Taquicardia Ventricular/terapia , Ablación por CatéterRESUMEN
Resumen: Reportamos el caso de un hombre de 67 años, con múltiples factores de riesgo cardiovascular, quien en el año 2015 presentó muerte súbita por fibrilación ventricular sin lesiones coronarias significativas, tras lo cual se implantó un desfibrilador automático. En el año 2019 presentó un nuevo episodio de fibrilación ventricular en relación con síndrome coronario agudo con supradesnivel del ST localizado en pared anterior, registrado y adecuadamente resuelto por el dispositivo. Se demostró una oclusión aterotrombótica en la porción proximal de la arteria descendente anterior. Fue precoz y exitosamente manejado con angioplastía coronaria percutánea e implante de stent fármaco activo, guiado por tomografía por coherencia óptica intracoronaria. A las 48 horas post angioplastía, presentó episodio de taquicardia ventricular polimorfa reconocido y tratado por el cardiodesfibrilador, sin consecuencias. Electivamente se efectuó angioplastía e implante de stent metálico en arteria coronaria derecha distal, con buen resultado angiográfico. La posterior evolución del paciente fue satisfactoria, sin manifestaciones de insuficiencia cardíaca, angina ni arritmias.
Abstract: A 67-year-old man, with multiple cardiovascular risk factors who in 2015 presented sudden death due to ventricular fibrillation without significant coronary lesions, after which an implantable automatic defibrillator (ICD) was implanted. In 2019, he presented a new episode of ventricular fibrillation adequately resolved by the device, in relation to an acute coronary syndrome with ST elevation in the anterior wall of the left ventricle, due to atherothrombotic occlusion in the proximal portion of the anterior descending artery. He was early and successfully managed with percutaneous coronary angioplasty by the insertion of a drug eluting stent, implanted guided by intracoronary optical coherence tomography. Forty eight hours later, he presented an episode polymorphic ventricular tachycardia recognized and treated by the ICD. Angioplasty with a bare metal stent implantation were performed in the distal right coronary artery, with good angiographic results. The subsequent course was satisfactory, with no manifestations of heart failure, angina or arrhythmias.
Asunto(s)
Humanos , Masculino , Anciano , Fibrilación Ventricular/complicaciones , Muerte Súbita Cardíaca , Isquemia Miocárdica/complicaciones , Desfibriladores Implantables , Fibrilación Ventricular/terapia , Isquemia Miocárdica/terapia , Angioplastia , Electrocardiografía , Stents Liberadores de FármacosAsunto(s)
Humanos , Femenino , Anciano , Fibrilación Ventricular/terapia , Fibrilación Ventricular/diagnóstico por imagen , Paro Cardíaco/patología , Imagen por Resonancia Magnética/métodos , Radiografía Torácica/métodos , Desfibriladores Implantables , Vena Cava Superior Izquierda Persistente/diagnóstico por imagenRESUMEN
BACKGROUND: Double/dual defibrillation (DD) has been proposed as an alternative treatment for refractory ventricular fibrillation (VF). This topic has been poorly researched and data on survival rates are limited. OBJECTIVE: This systematic review and meta-analysis evaluates whether DD improves outcomes among patients with refractory VF in- and out-of-hospital cardiac arrest compared with standard defibrillation. METHODS: A literature search was conducted on July 20, 2019 using MEDLINE via PubMed, Embase, Scopus, and the Cochrane Database of Systematic Reviews. We gave all results as a pooled odds ratio (OR) and 95% confidence interval (CI). Heterogeneity was assessed by calculating the I2 statistic and was deemed significant for a p value of < 0.10 or I2 ≥ 50%. The quality of evidence was evaluated according to Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines. RESULTS: We included 27 records, of which 4 cohort studies totaling 1061 patients were included in the quantitative analysis. Of these, 20.5% (n = 217) received the intervention. DD had no effect on return of spontaneous circulation (OR 0.68; 95% CI 0.44-1.04; I2 = 41%, p = 0.08) (GRADE: Very low), survival to admission (OR 0.77; 95% CI 0.51-1.17; I2 = 18%, p = 0.22) (GRADE: Very low), or survival to discharge (OR 0.66; 95% CI 0.38-1.15; I2 = 0%, p = 0.14) (GRADE: Very low). CONCLUSIONS: DD did not improve any outcomes of interest. Therefore, it is imperative that a well-designed study in this area be conducted. Ideally, conducting a randomized controlled trial in this population should be attempted to obtain a higher level of scientific evidence.
Asunto(s)
Reanimación Cardiopulmonar , Servicios Médicos de Urgencia , Paro Cardíaco Extrahospitalario , Cardioversión Eléctrica , Hospitales , Humanos , Paro Cardíaco Extrahospitalario/terapia , Ensayos Clínicos Controlados Aleatorios como Asunto , Tasa de Supervivencia , Fibrilación Ventricular/terapiaRESUMEN
OBJECTIVES: The goal of this analysis was to pool data from published studies on outcomes after implantable cardioverter-defibrillator (ICD) therapy in patients with Chagas heart disease (CHD). BACKGROUND: CHD is characterized by a high burden of ventricular arrhythmias and an increased risk of sudden cardiac death. The indications for ICD are not well established. METHODS: An extensive literature search without language restrictions was performed to identify all studies on ICD therapy in patients with CHD. A random effects model was used to calculate percentages and 95% confidence intervals (CIs). RESULTS: Of 397 articles screened, 13 studies (all observational) were included. There were 1,041 patients (mean age at implantation 57 ± 11 years; 64% men), most of whom (92%) received an ICD for secondary prevention. Antiarrhythmic medication consisted of amiodarone (79%) and beta-blockers (44%). Overall, the annual all-cause mortality rate was 9.0% (95% CI: 6.9 to 11.7) in 2.8 ± 1.9 years of follow-up, and the annual sudden cardiac death rate was 2.0% (95% CI: 1.3 to 3.3) in 2.6 ± 1.9 years. In addition, 24.8% (95% CI: 15.7 to 37.0) of patients received 1 or more appropriate interventions (shocks or antitachycardia pacing), 4.7% (95% CI: 3.2 to 6.9) received inappropriate shocks, and 9.1% (95% CI: 5.5 to 14.7) had electric storms annually. CONCLUSIONS: In patients with an ICD, annual all-cause mortality rate was 9%. Appropriate ICD interventions and electric storms were frequent, occurring at a rate of 25% and 9% per year, respectively. Inappropriate ICD shocks were not infrequent (5% per year). The benefits and risks of ICD therapy in patients with CHD should be carefully weighed until data from better studies become available.
Asunto(s)
Cardiomiopatía Chagásica/terapia , Muerte Súbita Cardíaca/prevención & control , Desfibriladores Implantables , Taquicardia Ventricular/terapia , Fibrilación Ventricular/terapia , Antagonistas Adrenérgicos beta/uso terapéutico , Amiodarona/uso terapéutico , Antiarrítmicos/uso terapéutico , Muerte Súbita Cardíaca/epidemiología , Cardioversión Eléctrica , Humanos , Prevención Primaria , Prevención Secundaria , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/epidemiología , Fibrilación Ventricular/diagnóstico , Fibrilación Ventricular/epidemiologíaRESUMEN
A incidência exata de parada cardiorrespiratória (PCR) mesmo em países com registros clínicos bem estruturados ainda é desconhecida, mas as estimativas variam de 180.000 a mais de 450.000 mortes anuais. A etiologia mais comum da PCR é a doença cardiovascular isquêmica que ocasiona no desenvolvimento de arritmias letais. A sobrevivência decorrente da PCR apresenta desfechos divergentes. No cenário extra-hospitalar, os estudos relataram taxas de sobrevida de 1% a 6%. Três revisões sistemáticas de alta hospitalar sobre a PCR extra-hospitalar mostraram 5% a 10% de sobrevida entre aqueles tratados através de serviços médicos de emergência e 15% quando o distúrbio do ritmo era a fibrilação ventricular (FV). O suporte básico de vida consiste em ressuscitação cardiopulmonar (RCP) e, quando disponível, desfibrilação com desfibrilador externo automático (DEA). As chaves para a sobrevivência após a PCR são reconhecimento e tratamento precoces, especificamente, início imediato de excelente RCP e desfibrilação precoce. O presente artigo discutirá os princípios do suporte básico de vida em adultos do pré-hospitalar à sala de emergência, conforme descritos nas Diretrizes de Ressuscitação Cardiopulmonar e Atendimento Cardiovascular de Emergência do ILCOR e AHA, atualizadas em novembro de 2017
The exact incidence of cardiorespiratory arrest (CRA) even in countries with well-structured clinical records is still unknown, but estimates range from 180,000 to over 450,000 annual deaths. The most common etiology of CRA is ischemic cardiovascular disease, resulting in the development of lethal arrhythmias. Survival of CRA shows divergent outcomes. In the out-of-hospital setting, studies have reported survival rates of 1% to 6%. Three systematic reviews of hospital discharge on extra-hospital CRA showed 5% to 10% survival between those treated by emergency medical services and 15% when the rhythm disorder was ventricular fibrillation (VF). Basic life support consists of cardiopulmonary resuscitation (CPR) and, when available, defibrillation with an automatic external defibrillator (AED). The keys to survival of CRA are early recognition and treatment, specifically, immediate onset of excellent CPR and early defibrillation. This article will discuss the basics of adult life support from prehospital to emergency room, as outlined in the ILCOR and AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, updated in November 2017
Asunto(s)
Humanos , Masculino , Femenino , Reanimación Cardiopulmonar/métodos , Guías como Asunto/normas , Tratamiento de Urgencia/métodos , Atención Prehospitalaria/métodos , Arritmias Cardíacas , Fibrilación Ventricular/terapia , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/etiología , Cardioversión Eléctrica/métodos , Enfermedades Cardiovasculares/etiología , Epinefrina/uso terapéutico , Desfibriladores Implantables , Desfibriladores , Electrodos , Paro Cardíaco/etiología , Amiodarona/uso terapéuticoRESUMEN
ABSTRACTDual sequential external defibrillation (DSED) is the process of near simultaneous discharge of two defibrillators with differing pad placement to terminate refractory arrhythmias. Previously used in the electrophysiology suite, this technique has recently been used in the emergency department and prehospital setting for out-of-hospital cardiac arrest (OHCA). We present a case of successful DSED in the emergency department with neurologically intact survival to hospital discharge after refractory ventricular fibrillation (RVF) and review the putative mechanisms of action of this technique.
Asunto(s)
Desfibriladores , Servicio de Urgencia en Hospital/organización & administración , Paro Cardíaco Extrahospitalario/terapia , Fibrilación Ventricular/terapia , Electrocardiografía , Servicios Médicos de Urgencia , Humanos , Masculino , Persona de Mediana EdadRESUMEN
INTRODUCTION: The implantable cardioverter defibrillator had been increasing the survival of patients at high risk for sudden cardiac death. The subcutaneous implantable cardioverter defibrillator was developed to mitigate the complications inherent to lead placement into cardiovascular system. OBJECTIVE: To report the initial experience of 18 consecutive cases of subcutaneous implantable cardioverter defibrillator implantation showing the indications, potential pitfalls and perioperative complications. METHODS: Between September 2016 and March 2017, 18 patients with indication for primary and secondary prevention of sudden cardiac death, with no concomitant indication for artificial cardiac pacing, were included. RESULTS: The implantation of the subcutaneous implantable cardioverter defibrillator successfully performed in 18 patients. It was difficult to place the subcutaneous lead at the parasternal line in two patients. One patient returned a week after the procedure complaining about an increase in pain intensity at pulse generator pocket site, which was associated with edema, temperature rising and hyperemia. Two patients took antialgic medication for five days after surgery. A reintervention was necessary in one patient to replace the lead in order to correct inappropriate shocks caused by myopotential oversensing. CONCLUSION: In our initial experience, although the subcutaneous implantable cardioverter defibrillator implantation is a less-invasive, simple-accomplishment procedure, it resulted in a bloodier surgery perhaps requiring an operative care different from the conventional. Inappropriate shock by oversensing is a reality in this system, which should be overcame in order not to become a limiting issue for its indication.
Asunto(s)
Estimulación Cardíaca Artificial/métodos , Muerte Súbita Cardíaca/prevención & control , Desfibriladores Implantables , Cardioversión Eléctrica/instrumentación , Prevención Secundaria/instrumentación , Fibrilación Ventricular/terapia , Muerte Súbita Cardíaca/etiología , Desfibriladores Implantables/efectos adversos , Cardioversión Eléctrica/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Marcapaso Artificial , Resultado del Tratamiento , Fibrilación Ventricular/complicacionesRESUMEN
Abstract Introduction: The implantable cardioverter defibrillator had been increasing the survival of patients at high risk for sudden cardiac death. The subcutaneous implantable cardioverter defibrillator was developed to mitigate the complications inherent to lead placement into cardiovascular system. Objective: To report the initial experience of 18 consecutive cases of subcutaneous implantable cardioverter defibrillator implantation showing the indications, potential pitfalls and perioperative complications. Methods: Between September 2016 and March 2017, 18 patients with indication for primary and secondary prevention of sudden cardiac death, with no concomitant indication for artificial cardiac pacing, were included. Results: The implantation of the subcutaneous implantable cardioverter defibrillator successfully performed in 18 patients. It was difficult to place the subcutaneous lead at the parasternal line in two patients. One patient returned a week after the procedure complaining about an increase in pain intensity at pulse generator pocket site, which was associated with edema, temperature rising and hyperemia. Two patients took antialgic medication for five days after surgery. A reintervention was necessary in one patient to replace the lead in order to correct inappropriate shocks caused by myopotential oversensing. Conclusion: In our initial experience, although the subcutaneous implantable cardioverter defibrillator implantation is a less-invasive, simple-accomplishment procedure, it resulted in a bloodier surgery perhaps requiring an operative care different from the conventional. Inappropriate shock by oversensing is a reality in this system, which should be overcame in order not to become a limiting issue for its indication.
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Fibrilación Ventricular/terapia , Cardioversión Eléctrica/instrumentación , Estimulación Cardíaca Artificial/métodos , Muerte Súbita Cardíaca/prevención & control , Desfibriladores Implantables/efectos adversos , Prevención Secundaria/instrumentación , Marcapaso Artificial , Fibrilación Ventricular/complicaciones , Cardioversión Eléctrica/efectos adversos , Resultado del Tratamiento , Muerte Súbita Cardíaca/etiologíaRESUMEN
BACKGROUND: Frequent hospital attendances in patients with implantable cardioverter-defibrillators (ICDs) result in significant morbidity and health care costs. Current drugs to reduce ICD shocks and hospital visits have limited efficacy and considerable toxicity. We evaluated the efficacy and safety of azimilide, a novel oral class III antiarrhythmic, for use in ICD patients. METHODS: A total of 240 patients were enrolled in a prospective, randomized, double-blind, placebo-controlled trial to evaluate the effect of oral azimilide 75 mg daily in ICD patients with previously documented ventricular tachycardia or ventricular fibrillation, and a left ventricular ejection fraction ≤40%. The primary outcome metric was the adjudicated time-to-first unplanned cardiovascular (CV) hospitalization, or CV emergency department (ED) visit, or CV death. The trial was prematurely discontinued due to withdrawal of study sponsorship. RESULTS: Azimilide demonstrated numerical but statistically nonsignificant reductions in the primary composite outcome (odds ratio [OR] 0.79, 95% CI 0.44-1.44), unplanned CV hospitalizations (OR 0.75, 95% CI 0.41-1.38), ED visits (OR 0.68, 95% CI 0.35-1.31), and all-cause shocks (OR 0.58, 95% CI 0.32-1.05). The incidence of adverse events was lower in the azimilide group. Neutropenia was not observed (absolute neutrophil count <1000 µ/L), and there was one possible torsade de pointes case that led to a successful ICD discharge. CONCLUSION: The SHIELD-2 trial was statistically underpowered due to early trial termination and did not meet its primary objective. Despite this limitation, azimilide showed promise as a safe and effective drug in reducing all-cause shocks, unplanned hospitalizations, and ED visits in ICD patients.
Asunto(s)
Antiarrítmicos/uso terapéutico , Muerte Súbita Cardíaca/prevención & control , Desfibriladores Implantables , Insuficiencia Cardíaca/terapia , Hidantoínas/uso terapéutico , Piperazinas/uso terapéutico , Taquicardia Ventricular/terapia , Fibrilación Ventricular/terapia , Anciano , Enfermedades Cardiovasculares/mortalidad , Muerte Súbita Cardíaca/etiología , Método Doble Ciego , Terminación Anticipada de los Ensayos Clínicos , Cardioversión Eléctrica , Servicio de Urgencia en Hospital/estadística & datos numéricos , Femenino , Insuficiencia Cardíaca/complicaciones , Insuficiencia Cardíaca/fisiopatología , Hospitalización/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Modelos de Riesgos Proporcionales , Volumen Sistólico , Taquicardia Ventricular/etiología , Fibrilación Ventricular/etiologíaRESUMEN
BACKGROUND: In-hospital cardiac arrest (IHCA) is a major public health problem with significant mortality. A better understanding of where IHCA occurs in hospitals (intensive care unit [ICU] versus monitored ward [telemetry] versus unmonitored ward) could inform strategies for reducing preventable deaths. METHODS AND RESULTS: This is a retrospective study of adult IHCA events in the Get with the Guidelines-Resuscitation database from January 2003 to September 2010. Unadjusted analyses were used to characterize patient, arrest, and hospital-level characteristics by hospital location of arrest (ICU versus inpatient ward). IHCA event rates and outcomes were plotted over time by arrest location. Among 85 201 IHCA events at 445 hospitals, 59% (50 514) occurred in the ICU compared to 41% (34 687) on the inpatient wards. Compared to ward patients, ICU patients were younger (64±16 years versus 69±14; P<0.001) and more likely to have a presenting rhythm of ventricular tachycardia/ventricular fibrillation (21% versus 17%; P<0.001). In the ICU, mean event rate/1000 bed-days was 0.337 (±0.215) compared with 0.109 (±0.079) for telemetry wards and 0.134 (±0.098) for unmonitored wards. Of patients with an arrest in the ICU, the adjusted mean survival to discharge was 0.140 (0.037) compared with the unmonitored wards 0.106 (0.037) and telemetry wards 0.193 (0.074). More IHCA events occurred in the ICU compared to the inpatient wards and there was a slight increase in events/1000 patient bed-days in both locations. CONCLUSIONS: Survival rates vary based on location of IHCA. Optimizing patient assignment to unmonitored wards versus telemetry wards may contribute to improved survival after IHCA.
Asunto(s)
Reanimación Cardiopulmonar , Paro Cardíaco/epidemiología , Unidades de Cuidados Intensivos , Sistema de Registros , Taquicardia Ventricular/epidemiología , Fibrilación Ventricular/epidemiología , Factores de Edad , Anciano , Anciano de 80 o más Años , Femenino , Paro Cardíaco/mortalidad , Paro Cardíaco/terapia , Mortalidad Hospitalaria , Unidades Hospitalarias , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Tasa de Supervivencia , Taquicardia Ventricular/terapia , Telemetría , Estados Unidos/epidemiología , Fibrilación Ventricular/terapiaRESUMEN
A tempestade elétrica em portadores de cardiodesfibriladores implantáveis é a ocorrência de pelo menos três intervenções apropriadas, resultante de taquicardia ventricular ou fibrilação ventricular, em 24 horas. É preditor de mau prognóstico e a terapia varia de medicamentos até transplante cardíaco. Este estudo teve por objetivo revisar orientações de diagnóstico e prevenção, visando ao tratamento (farmacológico, intervencionista e cirúrgico) da tempestade elétrica em portadores desses dispositivos. Compilamos publicações no Medline/PubMed e em revistas nacionais. O tratamento das condições basais e desencadeantes, como insuficiência cardíaca e insuficiência coronária, reduziu a morte súbita. A miodarona, betabloqueadores, lidocaína e magnésio são a base terapêutica. A ablação por cateter reduz arritmias e choques, estabiliza o ritmo e melhora o prognóstico. A taquicardia ventricular com substrato permite a abordagem de um circuito estável. A compreensão dos mecanismos e as melhorias no mapeamento eletrofisiológico possibilitam seu uso na fibrilação ventricular. Diferentes condições necessitam de abordagem cirúrgica, eliminando focos arritmogênicos e/ou permitindo o remodelamento,utilizando ressincronização, tratamentos para coronariopatia, valvopatias e cardiopatias congênitas, ressecção endocárdica guiada por eletrofisiologia e transplante em pacientes refratários. Atuando no sistema nervoso, aneuromodulação é alternativa. Durante anestesia peridural torácica, a denervação simpática cardíaca tem efeitos consistentes e persistentes. De modo semelhante à denervação simpática renal, pode ser um novo horizonte. Concluímos que identificar a causa é fundamental. O tratamento dos fatores causais melhora o controle e o prognóstico. Amiodarona, bloqueadores beta-adrenérgicos, lidocaína e magnésio são opções. Procedimento ablativo deve ser ponderado para taquicardia e fibrilação ventricular. Abordagem cirúrgica e neuromodulação...
Electrical storm in patients with implantable cardioverter defibrillator is the occurrence of at least three appropriate interventions resulting from tachycardia or ventricular fibrillation within 24 hours. It a predictor of poor prognosis and its treatment may vary from drug therapy to heart transplantation. Our objectivewas to review diagnostic and prevention guidelines aiming at the treatment (drug therapy, interventional and surgical treatment) of electrical storm in patients using these devices. We analyzed publications from Medline/PubMed and Brazilian medical journals. The treatment of baseline conditions and triggers, such as heart failure and coronary insufficiency, reduced sudden death. Amiodarone, betablockers, lidocaine and magnesium are the therapeutic basis. Catheter ablation reduces shock and arrhythmia, stabilizes rhythm and improves prognosis. Ventricular tachycardia with substratum allows the approach of a stable circuit. Understanding the mechanismsand improvements in electrophysiological mapping enables the use of catheter ablation in ventricular fibrillation.Different conditions require a surgical approach, eliminating arrhythmogenic cores and/or allowing cardiac remodeling, using cardiac resynchronization therapy, treatment for coronary artery disease, valve disease,congenital heart disease, electrophysiology-guided endocardial resection and heart transplantation in refractory patients. Neuromodulation is an alternative that acts on the nervous system. During thoracic epidural anesthesia, cardiac sympathetic denervation has consistent and persisting effects. Similarly, renal denervation may be anotherfuture possibility. In conclusion, identifying the cause is essential. Treatment of baseline factors improves control and prognosis. Amiodarone, betablockers, lidocaine and magnesium are pharmacological options. Catheterablation may be considered for tachycardia and ventricular fibrillation. Surgical approach and neuromodulation...
Asunto(s)
Humanos , Arritmias Cardíacas/complicaciones , Arritmias Cardíacas/terapia , Cardioversión Eléctrica/métodos , Desfibriladores Implantables/efectos adversos , Taquicardia/complicaciones , Taquicardia/terapia , Ablación por Catéter/métodos , Antiarrítmicos/administración & dosificación , Fibrilación Ventricular/complicaciones , Fibrilación Ventricular/terapia , Prevención Secundaria/métodos , Simpatectomía/métodos , Terapia de Resincronización Cardíaca/métodosRESUMEN
BACKGROUND: Targeted automated external defibrillator (AED) programs have improved survival rates among patients who have an out-of-hospital cardiac arrest (OHCA) in US airports, as well as European and Japanese railways. The Sao Paulo (Brazil) Metro subway carries 4.5 million people per day. A targeted AED program was begun in the Sao Paulo Metro with the objective to improve survival from cardiac arrest. METHODS AND RESULTS: A prospective, longitudinal, observational study of all cardiac arrests in the Sao Paulo Metro was performed from September 2006 through November 2012. This study focused on cardiac arrest by ventricular arrhythmias, and the primary endpoint was survival to hospital discharge with minimal neurological impairment. A total of 62 patients had an initial cardiac rhythm of ventricular fibrillation. Because no data on cardiac arrest treatment or outcomes existed before beginning this project, the first 16 months of the implementation was used as the initial experience and compared with the subsequent 5 years of full operation. Return of spontaneous circulation was not different between the initial 16 months and the subsequent 5 years (6 of 8 [75%] vs. 39 of 54 [72%]; P=0.88). However, survival to discharge was significantly different once the full program was instituted (0 of 8 vs. 23 of 54 [43%]; P=0.001). CONCLUSIONS: Implementation of a targeted AED program in the Sao Paulo Metro subway system saved lives. A short interval between arrest and defibrillation was key for good long-term, neurologically intact survival. These results support strategic expansion of targeted AED programs in other large Latin American cities.
Asunto(s)
Reanimación Cardiopulmonar/instrumentación , Muerte Súbita Cardíaca/prevención & control , Desfibriladores , Cardioversión Eléctrica/instrumentación , Paro Cardíaco Extrahospitalario/terapia , Vías Férreas , Servicios Urbanos de Salud , Fibrilación Ventricular/terapia , Anciano , Brasil , Reanimación Cardiopulmonar/efectos adversos , Reanimación Cardiopulmonar/mortalidad , Cardioversión Eléctrica/efectos adversos , Cardioversión Eléctrica/mortalidad , Servicios Médicos de Urgencia , Femenino , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Paro Cardíaco Extrahospitalario/diagnóstico , Paro Cardíaco Extrahospitalario/mortalidad , Paro Cardíaco Extrahospitalario/fisiopatología , Admisión del Paciente , Alta del Paciente , Evaluación de Programas y Proyectos de Salud , Estudios Prospectivos , Recuperación de la Función , Factores de Riesgo , Factores de Tiempo , Tiempo de Tratamiento , Transporte de Pacientes , Resultado del Tratamiento , Fibrilación Ventricular/diagnóstico , Fibrilación Ventricular/mortalidad , Fibrilación Ventricular/fisiopatologíaRESUMEN
O uso na prática clínica de novas formas de terapia dos portadores de cardiopatia vem aumentando a sobrevida e melhorando sua qualidade de vida ao longo dos anos. O advento dos cardioversores-defibriladores implantáveis foi um marco no tratamento dos pacientes com cardiopatias graves e mais propensos a morte súbita, com redução da taxa de mortalidade nesses pacientes. Porém, surgiram novas questões no manejo desses pacientes, especialmente no que concerne o seguimento dos portadores desses dispositivos em relação à sua otimização para redução de terapias inapropriadas, melhora de qualidade psicossocial e a conduta frente a situações emergenciais representadas por arritmias frequentes, repetitivas erefratárias, como no caso da Tempestade Elétrica. O objetivo do presente trabalho é revisar as definições, epidemiologia e especialmente a conduta frente a esse grupo de pacientes, que deve aumentar nos próximos anos, com a maior prevalência das cardiopatias, especialmente a isquêmica, e o maior número de implantes de dispositivos cardíacos eletrônicos...
The use of new forms of therapy in patients with heart disease has increased the survival and quality of life of these patients in recent years. The advent of implantable cardioverter- defibrillators was a landmark in the treatment of patients with severe heart disease, who were more prone to sudden death, and led to a reduction in mortality rates among these patients. However, new issues emerged in the management of these patients, especially concerning the follow-up of cardioverter-defibrillator patients in terms of reducing inappropriate therapies, improving their quality of life, and managing emergency situations represented by frequent, repetitive and refractory arrhythmias, such as Electrical Storm. The purpose of this paper is to revise the definitions, epidemiology, and above all, the management of this group of patients, which is expected to grow in the coming years, with the greater prevalence of heart disease, especially ischemic heart disease, and thein creased use of electronic heart implants...